23585-49-1

Basic information

• Product Name: (1H-PYRAZOL-3-YL)METHANOL
• Synonyms: 3-(HYDROXYMETHYL)PYRAZOLE;1H-PYRAZOLE-3-METHANOL;(1H-PYRAZOL-3-YL)METHANOL;1H-pyarzole-3-methanol;3-HyroxyMethyl-1H-pyrazole;3-HyroxyMethyl-1H-pyrazol...;23585-49-1
• CAS NO: 23585-49-1
• Molecular Formula: C₄H₆N₂O
• Molecular Weight: 98.10324
• Product Categories: pharmacetical
• Mol File: 23585-49-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 184-185 °C
• Boiling Point: 326.8°Cat760mmHg
• Flash Point: 151.5°C
• Appearance: /
• Density: 1.311g/cm³
• Vapor Pressure: 8.54E-05mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: 2-8°C
• PKA: 13.59±0.10(Predicted)
• CAS DataBase Reference: (1H-PYRAZOL-3-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (1H-PYRAZOL-3-YL)METHANOL(23585-49-1)
• EPA Substance Registry System: (1H-PYRAZOL-3-YL)METHANOL(23585-49-1)

Safety Data

• Hazardous Substances Data: 23585-49-1(Hazardous Substances Data)

Usage

Chemical Properties

Colorless Liquid

InChI:InChI=1/C4H6N2O/c7-3-4-1-2-5-6-4/h1-2,7H,3H2,(H,5,6)

Upstream product

• 18350-44-2 4,4-diethoxy-but-2-yn-1-ol 
• 122609-00-1 1⁽²⁾H-pyrazole-3-carboxylic acid butyl ester 
• 107-19-7 propargyl alcohol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 1621-91-6 1H-pyrazole-3-carboxylic acid 
• 64-17-5 ethanol 
• 99805-29-5 4-tetrahydropyran-2-yloxy-but-2-ynal-diethylacetal 
• 15366-34-4 methyl 1H-pyrazole 3-carboxylate 
• 5932-27-4 ethyl 1H-pyrazole-3-carboxylate 
• 186581-53-3 diazomethane 
• 60-29-7 diethyl ether 

Downstream Products

• 1191923-32-6 C₂₃H₂₇N₅O₄ 
• 869558-95-2 (1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-3-yl)methanol 
• 3920-50-1 3-formylpyrazole 
• 1562342-97-5 (1-(3-bromo-4-methoxyphenyl)-1H-pyrazol-3-yl)methanol 
• 1202644-77-6 1-(7-(5-(hydroxymethyl)-1H-pyrazol-1-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethane-1,2-dione 
• 1202644-78-7 1-(7-(3-(hydroxymethyl)-1H-pyrazol-1-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-(5-(pyridin-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethane-1,2-dione 
• 102846-12-8 3-bromomethylpyrazole 
• 99939-07-8 1-Amino-1H-pyrazol-3-methanol 
• 23784-89-6 3-(chloromethyl)-1H-pyrazole 

Relevant articles and documents

Optimization and biological evaluation of 2-aminobenzothiazole derivatives as Aurora B kinase inhibitors

A strong relationship between abnormal functions of Aurora kinases and tumorigenesis has been reported for decades. Consequently, Aurora kinases serve as potential targets for anticancer agents. Here, we identified aminobenzothiazole derivatives as novel inhibitors of Aurora B kinase through bioisosteric replacement of the previous inhibitors, aminobenzoxazole derivatives. Most of the urea-linked aminobenzothiazole derivatives showed potent and selective inhibitory activity against Aurora B kinase over Aurora A kinase. Molecular modeling indicated that compound 15g bound well to the active site of Aurora B kinase and formed the essential hydrogen bonds. The potent compounds, 15g and 15k, were selected, and their biological effects were evaluated using HeLa cell lines. It was found that these compounds inhibited the phosphorylation of histone H3 at Ser10 and induced G2/M cell cycle arrest. We suggest that the reported compounds have the potential to be further developed as anticancer therapeutics.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.